Clinical Trial

A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study is being conducted to evaluate the efficacy, and safety of SHR-2017 Injection in Patients with Bone Metastases from Solid Tumors. To explore the reasonable dosage of SHR-2017 Injection for Bone Metastases from Solid Tumors
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-11; most recent amendment 2025-12-26.
Status change: Not Yet Recruiting → Recruiting 2025-07-09
Trial Details
NCT Number NCT07028268
Lead Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions For Prevention of Bone Events in Patients With Bone Metastases From Solid Tumors
Enrollment 210 participants
Start Date 2025-06-24
Primary Completion 2025-12 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2025-12-31